Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 1 | 487 | 47 | 47 | 17 |
| Cost of Goods | 0 | -60 | 95 | 61 | 66 |
| Gross Profit | 1 | 547 | -48 | -14 | -49 |
| Operating Expenses | 2,698 | 2,746 | 4,978 | 5,834 | 5,782 |
| Operating Income | -2,697 | -2,259 | -4,931 | -5,787 | -5,765 |
| Interest Expense | 0 | 0 | 0 | 0 | 526 |
| Other Income | -3,051 | -24,333 | -595 | -856 | 134 |
| Pre-tax Income | -5,748 | -26,592 | -5,526 | -6,643 | -6,157 |
| Income Tax | 11 | 12 | 3 | 4 | 6 |
| Net Income Continuous | -5,759 | -26,604 | -5,529 | -6,647 | -6,163 |
| Net Income | $-5,759 | $-26,604 | $-5,529 | $-6,647 | $-6,153 |
| EPS Basic Total Ops | 1,463.02 | -1,842.50 | -383.50 | -461.02 | -427.29 |
| EPS Basic Continuous Ops | 1,462.19 | -1,842.38 | -382.89 | -460.51 | -427.13 |
| EPS Diluted Total Ops | 1,463.02 | -1,842.50 | -383.50 | -461.02 | -427.29 |
| EPS Diluted Continuous Ops | 1,462.19 | -1,842.38 | -382.89 | -460.51 | -427.13 |
| EPS Diluted Before Non-Recurring Items | N/A | -1,844.08 | -382.30 | -461.03 | N/A |
| EBITDA(a) | $482 | $-579 | $-3,879 | $-4,801 | $-5,033 |